Critical Survey: Theravance Biopharma (NASDAQ:TBPH) and Mannatech (NASDAQ:MTEX)

Theravance Biopharma (NASDAQ:TBPH) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Theravance Biopharma and Mannatech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	5	2	0	2.29
Mannatech	1	0	0	0	1.00

Theravance Biopharma presently has a consensus price target of $21.40, suggesting a potential upside of 29.07%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Mannatech.

Institutional & Insider Ownership

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Valuation and Earnings

This table compares Theravance Biopharma and Mannatech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46 million	7.95	$105.89 million	$2.20	7.54
Mannatech	$108.04 million	0.10	-$15.21 million	($6.71)	-0.81

Theravance Biopharma has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theravance Biopharma and Mannatech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Mannatech	-11.97%	-2,383.34%	-40.24%

Summary

Theravance Biopharma beats Mannatech on 11 of the 14 factors compared between the two stocks.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.